We conducted a literature review by searching studies that examined the activation status of NRF2 in clinical samples from human AD/psoriasis, as well as experimental works in which the efficacy of therapies targeting the KEAP1-NRF2 system was analyzed in vivo/vitro. The gene discussed is NFE2L2; the disease is Alzheimer disease.